CYTOKINETICS INC (CYTK) Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Cytokinetics, Incorporated NASDAQ:CYTK Healthcare · Biotechnology
Mkt Cap $8.76B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Cytokinetics to Announce Third Quarter Results on November 4, 2026
Cytokinetics is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time, followed by a management conference call at 4:30 PM.
The call will be webcast on the company's website with an archived replay available for six months.
The release contains no financial results; it is a scheduling notice only.
• 11d ago AI analysis › Press Release
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics granted inducement stock options on 60,465 shares and RSUs on 40,084 shares to 29 new hires under Nasdaq Listing Rule 5635(c)(4).
Options carry a $63.92 exercise price, equal to the October 15, 2026 close, and vest over four years; RSUs vest over three years on a 40/40/20 schedule.
This is a routine new-hire equity grant with no earnings, pipeline, or strategic impact on the company.
• 13d ago AI analysis › Press Release ⚠ 2
Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Health Canada has approved MYQORZO (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults with NYHA class II-III symptoms.
This is the fifth regulatory approval for aficamten in less than a year, following approvals by the FDA and China NMPA in December 2025 and by the European Commission and UK MHRA earlier in 2026.
The Canadian authorization is supported by the pivotal Phase 3 SEQUOIA-HCM trial, which showed a statistically significant improvement in peak oxygen uptake (LSM difference 1.74 mL/kg/min; p=0.000002) and a well-tolerated profile.
The Canadian label carries a boxed warning for heart failure risk due to systolic dysfunction, and Cytokinetics plans to file a supplemental NDA for non-obstructive HCM in Q4 2026 based on positive ACACIA-HCM results.
• 13d ago AI analysis › Press Release ⚠ 3
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
Cytokinetics presented additional ACACIA-HCM analyses at the HFSA 2026 annual meeting, showing aficamten significantly improved a novel composite exercise-performance metric (BEAP-RS) versus placebo in non-obstructive HCM (p<0.001).
A responder analysis found 53% of aficamten patients achieved a clinically meaningful response in three or more domains versus 13% on placebo, with results previously published in Circulation.
Safety data showed LVEF <50% in 10.5% of aficamten patients versus 0.8% on placebo and heart-failure SAEs in 4.7% versus 1.2%, events concentrated during dose titration; the company still plans to submit an sNDA to the FDA for nHCM this quarter.
• 20d ago AI analysis › Press Release
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
Cytokinetics announced four presentations, including two late-breaking clinical research talks, at the HFSA Annual Scientific Meeting 2026 in Phoenix from October 9-12.
The late-breaking talks cover global efficacy and exercise performance results of aficamten in non-obstructive HCM from the Phase 3 ACACIA-HCM trial; two additional orals cover SEQUOIA-HCM right ventricular function and ACACIA-HCM dosing and safety data.
Following positive topline ACACIA-HCM results, the company plans to submit a Supplemental New Drug Application for aficamten in nHCM in Q4 2026, making the meeting data a precursor to that regulatory step.
• 0mo ago AI analysis › Press Release ⚠ 1
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics launched ASPEN-HCM, a multicenter observational real-world study evaluating MYQORZO (aficamten) in adults with symptomatic obstructive hypertrophic cardiomyopathy.
The UCSF-led study will enroll roughly 400 patients across 13 cardiology practices and HCM centers over an anticipated 12-to-36-month period, tracking safety, effectiveness, and healthcare resource utilization.
MYQORZO carries a Boxed WARNING for heart-failure risk and is available only through a REMS program. Separately, the company plans a sNDA submission in Q4 2026 for aficamten in non-obstructive HCM following positive ACACIA-HCM Phase 3 results.
• 1mo ago AI analysis › Press Release
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics granted stock options to purchase 52,834 shares and 35,025 restricted stock units to 23 new employees as material inducements to employment under Nasdaq Listing Rule 5635(c)(4).
The options carry a $69.31 exercise price, equal to the September 15, 2026 closing price, a 10-year term, and four-year vesting; the RSUs vest over three years on a 40%/40%/20% schedule.
This is routine equity-compensation boilerplate with immaterial dilution and no new business, financial, or pipeline information.
• 1mo ago AI analysis › Press Release
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
Cytokinetics announced a call for proposals for its ninth annual Communications Grant Program, which awards grants to patient advocacy organizations serving the hypertrophic cardiomyopathy (HCM) and heart failure communities.
Applications are due October 2, 2026, with recipients to be announced in January 2027; the 2026 grant recipients were Camp Taylor and The Canadian SADS Foundation.
The release contains no new financial, regulatory, or clinical data — grant amounts were not disclosed, and the pipeline details cited (MYQORZO/aficamten approvals and a planned Q4 2026 sNDA submission for non-obstructive HCM) are pre-existing boilerplate. This is low-signal corporate-responsibility news for CYTK.
• 1mo ago AI analysis › Press Release
Cytokinetics to Participate in September Investor Conferences
Cytokinetics management will participate in four September investor conferences, with fireside chats at the Citi 2026 BioPharma Back to School Conference (Sept 9), Cantor Global Healthcare Conference (Sept 10), Morgan Stanley 24th Annual Global Healthcare Conference (Sept 14), and Bernstein 3rd Annual Healthcare Forum (Sept 23), all in New York.
Live webcasts of the fireside chats will be available through the Investors & Media section of the Cytokinetics website, with replays archived for 90 days.
The release contains no new financial or clinical data; its boilerplate section reiterates plans to submit a supplemental New Drug Application in Q4 2026 for aficamten in non-obstructive HCM following positive Phase 3 ACACIA-HCM results, alongside approvals of MYQORZO in the U.S., China, EU, and UK for obstructive HCM.
• 1mo ago AI analysis › Press Release ⚠ 2
Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics presented additional analyses from the Phase 3 ACACIA-HCM and MAPLE-HCM trials at the ESC Congress 2026, further supporting the efficacy of aficamten across both non-obstructive and obstructive HCM patient populations.
In the ACACIA-HCM trial, aficamten demonstrated improvements in cardiac structure and diastolic function, including a statistically significant reduction in left ventricular wall thickness of 0.2 cm at the end of treatment.
The MAPLE-HCM analysis showed aficamten consistently outperformed metoprolol in improving exercise capacity regardless of prior beta-blocker use, with a mean treatment difference of +2.3 mL/kg/min.
Based on these results, the company remains on track to submit a Supplemental New Drug Application for aficamten in non-obstructive HCM in the fourth quarter of 2026.
• 2mo ago AI analysis › Press Release ● Major ⚠ 2
Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine
Cytokinetics announced positive top-line results from the Phase 3 ACACIA-HCM trial, demonstrating that aficamten met both dual primary endpoints with statistically significant improvements in patient-reported symptoms and exercise capacity compared to placebo.
Based on these results, which were simultaneously published in The New England Journal of Medicine, the company plans to submit a supplemental New Drug Application to the FDA for the non-obstructive HCM indication in the fourth quarter of 2026.
Safety data showed aficamten was generally well-tolerated, although a higher incidence of reduced left ventricular ejection fraction and serious adverse events was observed compared to the placebo group.
• 2mo ago AI analysis › Press Release
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics announced that the primary results from the Phase 3 ACACIA-HCM trial of aficamten in non-obstructive HCM will be presented as a Hot Line session at the ESC Congress 2026 in Munich.
The company will also host two Late-Breaking Science presentations, detailing aficamten's effect on cardiac structure and comparative data from the MAPLE-HCM trial.
An in-person and virtual investor event is scheduled for August 28 to discuss the clinical data being presented at the congress.
• 2mo ago AI analysis › Press Release
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics granted inducement awards to 12 new employees, consisting of options for 27,565 shares and 18,273 RSUs.
The options have an exercise price of $74.13, equal to the closing price on the grant date, and vest over four years, while RSUs vest over three years.
These grants were made under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment for individuals who started in July and August 2026.
• 2mo ago AI analysis › Press Release ● Major ⚠ 4
Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
Cytokinetics reported $25.3 million in MYQORZO net product revenue for Q2, with over 1,500 patients dispensed and more than 700 unique prescribers, signaling strong commercial uptake following launch.
The pivotal Phase 3 ACACIA-HCM trial met its dual primary endpoints for non-obstructive HCM, positioning the company to submit a supplemental NDA in Q4 2026; safety data noted LVEF <50% in 10% of participants versus 1% on placebo.
The company ended the quarter with $1.7 billion in cash, bolstered by a $760 million net proceeds offering, and raised full-year expense guidance to $860-$890 million to support commercial readiness.
• 2mo ago AI analysis › Press Release ● Major
Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales
Cytokinetics received marketing authorisation from the UK MHRA for MYQORZO (aficamten) to treat symptomatic obstructive hypertrophic cardiomyopathy in adult patients.
NICE also issued positive guidance recommending the drug for eligible adults in England and Wales, establishing a reimbursement pathway.
The authorization was supported by Phase 3 SEQUOIA-HCM data showing a statistically significant improvement in peak oxygen uptake versus placebo.
Commercial availability through the NHS is expected later this year.
• 3mo ago AI analysis › Press Release
Cytokinetics to Announce Second Quarter Results on August 6, 2026
Cytokinetics announced that it will report its second quarter 2026 financial results on August 6, 2026 at 4:00 PM Eastern Time.
Senior management will host a conference call at 4:30 PM ET on the same day to discuss the financial results and provide business updates.
The event will be webcast via the Investors & Media section of the company's website, with an archived replay available for six months.
• 3mo ago AI analysis › Press Release
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics granted inducement awards consisting of 21,220 stock options and 14,067 restricted stock units to 10 new employees hired in June and July 2026.
The stock options have an exercise price of $82.62 per share, equal to the closing price on July 15, 2026, and vest over four years. The RSUs vest over three years on a 40/40/20 schedule.
These awards were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
• 3mo ago AI analysis › Press Release ● Major
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics will present primary results from the pivotal Phase 3 ACACIA-HCM trial of aficamten in non-obstructive hypertrophic cardiomyopathy at the ESC Congress 2026.
The data, described as positive topline results, will be featured in a Hot Line presentation on August 28, alongside two additional late-breaking science abstracts on cardiac structure and comparative efficacy.
The company plans to discuss these results with the FDA and other regulatory authorities to support potential label expansion for its approved drug MYQORZO.
• 3mo ago AI analysis › Press Release
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics granted inducement awards to 12 new employees, including options to purchase 24,784 shares and 16,429 RSUs.
The options have an exercise price of $71.38 per share and vest over four years, while RSUs vest over three years.
The awards were made under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment.
• 4mo ago AI analysis › Press Release
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
Cytokinetics announced a call for proposals for its annual Corporate Giving Program, with an application deadline of August 3, 2026.
The program offers individual charitable donations of up to $20,000 to qualified 501(c)(3) non-profits in the U.S.
Funding targets initiatives in cardiovascular health equity, science education, and essential services for at-risk communities in the Bay Area and Greater Philadelphia.
• 4mo ago AI analysis › Press Release ● Major
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany
Cytokinetics has launched MYQORZO (aficamten) commercially in Germany, marking the first European availability of its approved cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy (oHCM).
The launch follows European Commission approval in February 2026, which was based on the pivotal Phase 3 SEQUOIA-HCM trial showing robust efficacy and safety.
This expansion into the EU complements existing approvals in the U.S. and China, significantly broadening the global addressable market for the company's lead asset.
• 5mo ago AI analysis › Press Release
Cytokinetics to Participate in June Investor Conferences
Cytokinetics management will participate in two investor conferences in June 2026.
The company will hold a fireside chat at the Jefferies Global Healthcare Conference on June 3 in New York.
A second fireside chat is scheduled for the Goldman Sachs 47th Annual Global Healthcare Conference on June 8 in Miami Beach.
• 5mo ago AI analysis › Press Release
Cytokinetics to Hold Annual Meeting of Stockholders
Cytokinetics will hold its Annual Meeting of Stockholders on May 27, 2026, at its South San Francisco headquarters.
CEO Robert I. Blum is scheduled to present an overview of the company’s performance immediately following the meeting.
Stockholders of record as of March 31, 2026, are eligible to vote or attend in person, with a proxy deadline of May 26, 2026.
• 5mo ago AI analysis › Press Release
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cytokinetics granted stock options for 20,807 shares and 13,793 RSUs to eight new employees.
The awards were issued as material inducements to employment under Nasdaq Listing Rule 5635(c)(4), with options priced at $75.85 per share.
This is a routine compliance disclosure for hiring compensation and does not represent a material strategic or financial event.
• 5mo ago AI analysis › Press Release
Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)
Cytokinetics will host the third annual Contemporary Landscapes in Muscle Biology (CLIMB) symposium on May 29, 2026, from 8:00 AM to 5:00 PM Pacific Time at the Mission Bay Conference Center in San Francisco, CA.
Registration for the symposium is open at no cost to attendees, but capacity is limited and registration must be completed by May 22, 2026.
CLIMB is an annual one-day in-person research symposium that brings together scientists, researchers, and emerging professionals to share innovative research in muscle biology, with a focus on advancing the field and promoting interdisciplinary dialogue.
• 5mo ago AI analysis › Press Release
Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
globenewswire.com • 5mo ago Press Release ● Major
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026
globenewswire.com • 5mo ago Press Release
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million
Cytokinetics closed an underwritten public offering of 11,338,028 shares of its common stock, including the full exercise of the underwriters' option to purchase an additional 1,478,873 shares.
The offering was priced at $71.00 per share, resulting in gross proceeds of approximately $805 million before underwriting discounts and commissions.
Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan, and Jefferies acted as joint book-running managers, with Mizuho as lead co-manager and several other firms as co-managers.
• 5mo ago AI analysis › Press Release ● Major
Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock
Cytokinetics priced an upsized public offering of 9.86 million shares at $71.00 per share, expecting gross proceeds of approximately $700 million.
The deal includes a 30-day option for underwriters to purchase an additional 1.48 million shares and is expected to close on May 8, 2026.
Morgan Stanley, Goldman Sachs, J.P. Morgan, and Jefferies are acting as joint book-running managers for the offering.
• 5mo ago AI analysis › Press Release ● Major
Cytokinetics Announces Proposed Public Offering of Common Stock
Cytokinetics announced a proposed underwritten public offering of approximately $650 million of common stock, subject to market conditions.
The company expects to grant underwriters a 30-day option to purchase up to an additional 15% of the shares sold.
Morgan Stanley, Goldman Sachs, J.P. Morgan, and Jefferies are acting as joint book-running managers for the proposed offering.
• 5mo ago AI analysis › Press Release ● Critical ⚠ 1
Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
Cytokinetics reported first-quarter total revenue of $19.4 million, driven by $4.8 million in net product sales from the initial U.S. launch of MYQORZO and an $11.9 million milestone payment from Bayer.
Management highlighted strong early commercial traction with over 275 prescribers and approximately 680 patients treated in the first partial quarter, alongside positive Phase 3 results for ACACIA-HCM showing aficamten improved symptoms and exercise performance in non-obstructive HCM.
The company ended the quarter with approximately $1.1 billion in cash, down $144 million, and maintained its full-year 2026 financial guidance for combined R&D and SG&A expenses.
• 5mo ago AI analysis › Press Release ● Major
Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
globenewswire.com • 5mo ago Press Release ● Major
Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026
Cytokinetics will announce topline results from the ACACIA-HCM pivotal Phase 3 trial of aficamten in non-obstructive HCM on May 5, 2026.
A conference call and webcast is scheduled for 8:00 AM Eastern Time to discuss the data.
Aficamten is already approved for obstructive HCM as MYQORZO; this readout tests its efficacy in the non-obstructive population.
• 5mo ago AI analysis › Press Release
Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress
Cytokinetics announced nine presentations at the ESC Heart Failure 2026 Congress, including a late-breaking science oral presentation on MYQORZO (aficamten).
The presentations cover analyses from the MAPLE-HCM, SEQUOIA-HCM, FOREST-HCM, and GALACTIC-HF trials, focusing on clinical outcomes and economic burden in HCM and heart failure.
Scheduled for May 9–12 in Barcelona, the data will provide further insights into the efficacy and safety of the company's cardiac myosin inhibitors.
• 6mo ago AI analysis › Press Release
Cytokinetics to Announce First Quarter Results on May 5, 2026
Cytokinetics scheduled the release of its first quarter 2026 financial results for May 5, 2026, at 4:00 PM Eastern Time.
Senior management will host a conference call at 4:30 PM Eastern Time to discuss the financial results and provide business updates.
The call will be webcast via the company’s Investors & Media section, with an archived replay available for six months.
• 6mo ago AI analysis › Press Release
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
globenewswire.com • 6mo ago 
